AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

(2020) Maria L. Lotsberg et al.   Journal of Thoracic Oncology

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

(2020) Lecia V Sequist et al.   LANCET ONCOLOGY

Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

(2020) Gaozhi Chen et al.   Frontiers in Pharmacology

Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between

(2020) Antonio Passaro et al.   CANCER

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

(2020) Jacqueline H. Starrett et al.   CANCER RESEARCH

Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas

(2020) Michael M. Fisher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines

(2019) Tianxiang Chen et al.   Thoracic Cancer

FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells

(2019) Kentaro Miura et al.   Oncotarget

A disassembling strategy overcomes the EPR effect and renal clearance dilemma of the multifunctional theranostic nanoparticles for cancer therapy

(2019) Yanbing Wang et al.   BIOMATERIALS

PH sensitive shell-core platform block DNA repair pathway to amplify irreversible DNA damage of triple negative breast cancer

(2019) Yang Dong et al.   ACS Applied Materials & Interfaces

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer

(2018) Tingting Lv et al.   Acta Biomaterialia

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Mechanisms and context underlying the role of autophagy in cancer metastasis

(2018) Christopher M. Dower et al.   Autophagy

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

(2018) Clotilde Chatre et al.   DRUG SAFETY

Loss ofFgfr1in chondrocytes inhibits osteoarthritis by promoting autophagic activity in temporomandibular joint

(2018) Zuqiang Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

EGFR-TKIs resistance via EGFR-independent signaling pathways

(2018) Qian Liu et al.   Molecular Cancer

Third generation EGFR TKIs: current data and future directions

(2018) Chee-Seng Tan et al.   Molecular Cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer

(2018) Kaixuan Wang et al.   ONCOGENE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis

(2018) Qiaoyan Tan et al.   International Journal of Biological Sciences

Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins

(2018) Marcello Monti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Life, death and autophagy

(2018) Johnna Doherty et al.   NATURE CELL BIOLOGY

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

(2017) Hong Yuan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer

(2017) Surein Arulananda et al.   Journal of Thoracic Oncology

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells

(2017) K R Jakobsen et al.   Oncogenesis

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives

(2016) Remington L. Nevin et al.   MALARIA JOURNAL

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)

(2016) Michael F. Marmor et al.   OPHTHALMOLOGY

Therapeutics Targeting FGF Signaling Network in Human Diseases

(2016) Masaru Katoh   TRENDS IN PHARMACOLOGICAL SCIENCES

Mechanisms of Acquired Resistance to AZD9291

(2015) Tae Min Kim et al.   Journal of Thoracic Oncology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Beclin 1 regulates growth factor receptor signaling in breast cancer

(2015) R A Rohatgi et al.   ONCOGENE

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

(2015) Koichi Azuma et al.   Oncotarget

Tumor Vessel Normalization by Chloroquine Independent of Autophagy

(2014) Hannelore Maes et al.   CANCER CELL

PEG–lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication

(2014) Kanwaldeep K. Gill et al.   JOURNAL OF DRUG TARGETING

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering

(2014) Dan Fu et al.   Nature Chemistry

Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy

(2013) T. Kimura et al.   CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

(2013) Hideki Terai et al.   MOLECULAR CANCER RESEARCH

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

(2013) X Sui et al.   Cell Death & Disease

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

Converting Cancer Therapies into Cures: Lessons from Infectious Diseases

(2012) Michael S. Glickman et al.   CELL

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

(2012) Pasi A. Jänne et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells

(2012) RUYONG YAO et al.   Molecular Medicine Reports

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer

(2011) Yaara Gorzalczany et al.   CANCER LETTERS

Autophagy: Renovation of Cells and Tissues

(2011) Noboru Mizushima et al.   CELL

FRS2α-Mediated FGF Signals Suppress Premature Differentiation of Cardiac Stem Cells Through Regulating Autophagy Activity

(2011) Jue Zhang et al.   CIRCULATION RESEARCH

Principles and Current Strategies for Targeting Autophagy for Cancer Treatment

(2011) R. K. Amaravadi et al.   CLINICAL CANCER RESEARCH

Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies

(2009) V. Raja Solomon et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Characterization of a multifunctional PEG-based gene delivery system containing nuclear localization signals and endosomal escape peptides

(2008) Nicole M. Moore et al.   Acta Biomaterialia